EA202192183A1 - Композиции, обладающие активностью удаления липофусцина из клеток сетчатки - Google Patents
Композиции, обладающие активностью удаления липофусцина из клеток сетчаткиInfo
- Publication number
- EA202192183A1 EA202192183A1 EA202192183A EA202192183A EA202192183A1 EA 202192183 A1 EA202192183 A1 EA 202192183A1 EA 202192183 A EA202192183 A EA 202192183A EA 202192183 A EA202192183 A EA 202192183A EA 202192183 A1 EA202192183 A1 EA 202192183A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- lipofuscin
- compositions
- removal activity
- retina cells
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814028P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/020805 WO2020180872A1 (en) | 2019-03-05 | 2020-03-03 | Compositions of matter with activity to remove lipofuscin from retinal cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192183A1 true EA202192183A1 (ru) | 2022-01-14 |
Family
ID=72337111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192183A EA202192183A1 (ru) | 2019-03-05 | 2020-03-03 | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220118002A1 (https=) |
| EP (1) | EP3934660A4 (https=) |
| JP (1) | JP7573881B2 (https=) |
| KR (1) | KR20210142651A (https=) |
| CN (1) | CN113747902A (https=) |
| AU (1) | AU2020232266A1 (https=) |
| BR (1) | BR112021017529A2 (https=) |
| CA (1) | CA3132466A1 (https=) |
| CO (1) | CO2021012267A2 (https=) |
| EA (1) | EA202192183A1 (https=) |
| IL (1) | IL286002A (https=) |
| MX (1) | MX2021010650A (https=) |
| PH (1) | PH12021552131A1 (https=) |
| SG (1) | SG11202109541YA (https=) |
| WO (1) | WO2020180872A1 (https=) |
| ZA (1) | ZA202106559B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3205822A1 (en) * | 2021-01-22 | 2022-07-28 | Marcelo M. NOCIARI | Compositions and methods for the identification of compounds that protect against lipofuscin cytotoxicity |
| AU2023420130A1 (en) * | 2022-12-30 | 2025-08-14 | Cornell University | Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases |
| CN116253809B (zh) * | 2023-04-19 | 2024-11-05 | 广州润虹医药科技股份有限公司 | 一种去除壳聚糖中内毒素的方法 |
| WO2025147228A1 (en) * | 2024-01-02 | 2025-07-10 | Alkeus Pharmaceuticals, Inc. | Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| US8679511B2 (en) * | 2009-10-01 | 2014-03-25 | Duquesne University of the Holy Spririt | In-situ gel ophthalmic drug delivery system of estradiol or other estrogen for prevention of cataracts |
| WO2011072141A1 (en) * | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| US10463687B2 (en) * | 2011-01-20 | 2019-11-05 | Cornell University | Treatments for retinal disorders |
| KR101423631B1 (ko) * | 2012-08-17 | 2014-07-25 | 주식회사파마킹 | 에스-알릴엘-시스테인을 유효성분으로 포함하는 안질환 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 |
| WO2014152959A1 (en) * | 2013-03-14 | 2014-09-25 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| WO2016168772A1 (en) | 2015-04-17 | 2016-10-20 | Sens Research Foundation, Inc. | Cyclodextrin compounds for the prevention and treatment of aging |
| GB2556082A (en) | 2016-11-18 | 2018-05-23 | Warneford Healthcare Ltd | Ophthalmic composition |
-
2020
- 2020-03-03 AU AU2020232266A patent/AU2020232266A1/en not_active Abandoned
- 2020-03-03 US US17/436,023 patent/US20220118002A1/en active Pending
- 2020-03-03 WO PCT/US2020/020805 patent/WO2020180872A1/en not_active Ceased
- 2020-03-03 BR BR112021017529A patent/BR112021017529A2/pt not_active Application Discontinuation
- 2020-03-03 EP EP20767194.2A patent/EP3934660A4/en active Pending
- 2020-03-03 JP JP2021552728A patent/JP7573881B2/ja active Active
- 2020-03-03 EA EA202192183A patent/EA202192183A1/ru unknown
- 2020-03-03 PH PH1/2021/552131A patent/PH12021552131A1/en unknown
- 2020-03-03 KR KR1020217031603A patent/KR20210142651A/ko not_active Ceased
- 2020-03-03 CN CN202080031946.8A patent/CN113747902A/zh active Pending
- 2020-03-03 CA CA3132466A patent/CA3132466A1/en active Pending
- 2020-03-03 MX MX2021010650A patent/MX2021010650A/es unknown
- 2020-03-03 SG SG11202109541YA patent/SG11202109541YA/en unknown
-
2021
- 2021-08-31 IL IL286002A patent/IL286002A/en unknown
- 2021-09-07 ZA ZA2021/06559A patent/ZA202106559B/en unknown
- 2021-09-20 CO CONC2021/0012267A patent/CO2021012267A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3934660A4 (en) | 2022-11-23 |
| JP7573881B2 (ja) | 2024-10-28 |
| WO2020180872A1 (en) | 2020-09-10 |
| CA3132466A1 (en) | 2020-09-10 |
| PH12021552131A1 (en) | 2022-08-22 |
| KR20210142651A (ko) | 2021-11-25 |
| CN113747902A (zh) | 2021-12-03 |
| US20220118002A1 (en) | 2022-04-21 |
| EP3934660A1 (en) | 2022-01-12 |
| ZA202106559B (en) | 2025-01-29 |
| IL286002A (en) | 2021-10-31 |
| JP2022525007A (ja) | 2022-05-11 |
| AU2020232266A1 (en) | 2021-09-23 |
| SG11202109541YA (en) | 2021-09-29 |
| BR112021017529A2 (pt) | 2021-11-09 |
| MX2021010650A (es) | 2021-12-10 |
| CO2021012267A2 (es) | 2021-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA202192183A1 (ru) | Композиции, обладающие активностью удаления липофусцина из клеток сетчатки | |
| ZA202102488B (en) | Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders | |
| EA202190661A1 (ru) | Агонисты фарнезоидного х-рецептора для лечения заболевания | |
| EP4491229A3 (en) | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases | |
| EA201690212A8 (ru) | Способы лечения или профилактики офтальмологических патологических состояний | |
| PH12021550621A1 (en) | Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness | |
| MX2025004366A (es) | Composiciones farmaceuticas de inhibidores de bcl para usarse en la promocion de la reparacion vascular en el ojo de sujetos con retinopatia diabetica, edema macular diabetico, degeneracion macular relacionada con la edad, atrofia geografica, o retinopatia del prematuro | |
| EA201100654A1 (ru) | Соединения для лечения офтальмологических заболеваний и расстройств | |
| JOP20170147B1 (ar) | تركيبة عينية تشتمل على زيت الخروع ودهون ثلاثية متوسطة السلسلة | |
| EP4335418A3 (en) | Compositions and methods for treating pterygium | |
| EA202092779A1 (ru) | Замещенные дигидропиразолопиразинкарбоксамидные производные | |
| MX2025001445A (es) | Anticuerpos monoclonales anti-trkb y metodos de uso | |
| EA201990752A1 (ru) | Офтальмологический состав, содержащий цитиколин, переносимый липосомой, для лечения глаукомы | |
| EA201692402A1 (ru) | Лекарственные формы для местного применения и их использование | |
| MX2020012011A (es) | Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular. | |
| CY1111384T1 (el) | Διαμορφωση των επιπεδων εκφρασης toy trpv | |
| CO2019012336A2 (es) | Métodos y composiciones para tratar enfermedades asociadas a la retina mediante inhibidores de ccr3 | |
| MX2022001069A (es) | Composiciones y metodos para el tratamiento de la presbicia. | |
| EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
| MX2019011242A (es) | Farmacos y composiciones para el tratamiento de trastornos oculares. | |
| MX2023008613A (es) | Composiciones y metodos para la identificacion de compuestos que protegen contra la citotoxicidad de la lipofuscina. | |
| AR110947A1 (es) | Tratamiento de degeneración de la retina mediante el uso de células progenitoras | |
| CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
| MX2022006523A (es) | Composicion que comprende budesonida para uso oftalmico. | |
| MY208919A (en) | Anti-nrp1a antibodies and their uses for treating eye or ocular diseases |